{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021527","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.519287+00:00","generated_at":"2026-06-22T09:15:31.134459+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aeglea Q3 net loss $18.2M; cash $75.2M; pegtarviliase interim data expected Q4 2022","bullets":["Cash, equivalents and securities total $75.2M as of Sept 30, 2022; runway into Q4 2023.","Net loss $18.2M vs $20.3M in Q3 2021; revenue $0.2M from Immedica license.","Phase 1/2 pegtarviliase trial for Homocystinuria dosing cohort 3 at 1.35 mg/kg; interim data planned Q4 2022.","MAA for pegzilarginase (Arginase 1 Deficiency) submitted by partner Immedica currently under EMA review.","Corporate restructuring announced; Jim Kastenmayer appointed interim CEO; permanent CEO search underway."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021527","json":"https://secwatch.observer/filing/0000950170-22-021527.json","markdown":"https://secwatch.observer/filing/0000950170-22-021527.md","text":"https://secwatch.observer/filing/0000950170-22-021527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000095017022021527/0000950170-22-021527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000095017022021527/agle-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:15:31.134459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf0f647820bd06b3ba53133487d1075694d547ac","claim":"Spyre Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $0.2 million.","evidence_excerpt":"securities will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023. Aeglea recognized development fee revenues of $0.2 million in the third quarter of 2022 as a result of its license and supply agreement with Immedica for the commercial rights to pegzilarginase in certain territories outside the U.S. The","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017022021527/0000950170-22-021527-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$0.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}